Spago Nanomedical AB (publ) will present preclinical data for SpagoPix at the conference European Congress of Radiology (ECR) this week
The presentation, in the form of a poster with the title ”Efficacy and safety profile of SN132D, a novel nanoparticle MRI contrast agent”, includes preclinical data that collectively show that the product candidate SN132D is safe and efficient at dose levels corresponding to clinically relevant doses. The poster can be viewed here https://posterng.netkey.at/esr/viewing/index.php?module=viewing_poster&task=&pi=146808&searchkey=9d11a6231519212ecd4097e24f03a33c
ECR is the largest radiology conference in Europe which last year gathered over 28,000 participants from 130 countries. This year’s conference takes place in Vienna on February 27 to March 3 and puts women in focus.
A study was recently published in European Journal of Inorganic Chemistry showing that the signal strength (relaxivity) of SN132D is among the highest reported for manganese-containing contrast agents and far higher than those of the clinically used gadolinium-based agents.
On February 19, initiation of the first clinical trial with SN132D was approved by the Swedish Medical and Pharmaceutical Agency. The trial will be conducted at the Uppsala University Hospital in Sweden and will include up to 20 patients with breast cancer.
For further information, please contact Mats Hansen CEO Spago Nanomedical AB, +46 46 81188, email@example.com.